Serum lipoprotein changes following IGF-I normalization using a growth hormone receptor antagonist in acromegaly

Clinical Endocrinology

Volumn 56, Issue 3, 2002, Pages 303-311

  Parkinson, C ^a   Drake, W M ^b   Wieringa, G ^a   Yates, A P ^c   Besser, G M ^b   Trainer, P J ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^c MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; GROWTH HORMONE RECEPTOR ANTAGONIST; HIGH DENSITY LIPOPROTEIN; INSULIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; PEGVISOMANT; RECEPTOR BLOCKING AGENT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ACROMEGALY; ADULT; AGED; ARTICLE; CALCULATION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DISEASE ASSOCIATION; FEMALE; GROWTH HORMONE DEFICIENCY; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; MALE; PRIORITY JOURNAL; SAMPLING; STUDENT T TEST; WILCOXON SIGNED RANKS TEST;

ACROMEGALY; ADULT; AGED; CHOLESTEROL; FEMALE; FOLLOW-UP STUDIES; HUMAN GROWTH HORMONE; HUMANS; INSULIN; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR I; LIPOPROTEINS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; RECEPTORS, SOMATOTROPIN;

EID: 0036231569     PISSN: 03000664     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2265.2002.01460.x     Document Type: Article

References (66)

1. Epidemiology of acromegaly in the Newcastle region
2. Cholesterol and mortality. 30 Years of follow-up from the Framingham study
3. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men
4. An audit of outcome of treatment in acromegaly
5. Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984
6. Growth hormone in the regulation of hyperlipidemia
7. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations
8. Effects of octreotide on lipid metabolism in acromegaly
9. Growth hormone treatment of growth hormone-deficient adults results in a marked increase in Lp(a) and HDL cholesterol concentrations
10. In vivo growth hormone treatment stimulates secretion of very low density lipoprotein by the isolated perfused rat liver
11. Effect of storage at 4 degrees C and -20 degrees C on lipid, lipoprotein, and apolipoprotein concentrations
12. Effect of storage at -70 degrees C on lipid, lipoprotein and apolipoprotein concentrations
13. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
14. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women
15. Regulatory function of glucose and insulin on high-density lipoprotein cholesterol in normolipidemic subjects
16. Influence of insulin resistance, secretion, and clearance on serum cholesterol, triglycerides, lipoprotein cholesterol, and blood pressure in healthy men
17. Effect of short-term treatment with recombinant human growth hormone on lipids and lipoproteins in women and men without growth hormone disturbances
18. Carbohydrate tolerance and serum lipids in acromegaly before and during treatment with high dose octreotide
19. Serum apolipoprotein(a) correlates with growth hormone levels in Chinese patients with acromegaly
20. Elevated fibrinogen levels decrease following treatment of acromegaly
21. Growth hormone increases and insulin-like growth factor-I decreases circulating lipoprotein
22. Different effects of continuous and intermittent patterns of growth hormone administration on lipoprotein levels in growth hormone-deficient patients
23. HDL-cholesterol reductions associated with adult growth hormone replacement
24. Apolipoprotein E phenotype and lipoprotein(a) in familial hypercholesterolaemia: Implication for lipoprotein(a) metabolism
25. Effects of normalization of GH hypersecretion on lipoprotein(a) and other lipoprotein serum levels in acromegaly
26. Blood lipid concentrations and other cardiovascular risk factors: Distribution, prevalence, and detection in Britain
27. Homeostasis model assessment: Insulin resistance and B cell-function from fasting plasma glucose and insulin concentrations in man
28. Safety and efficacy of long-term octreotide therapy of acromegaly: Results of a multicenter trial in 103 patients - A clinical research center study
29. Serum lipids in acromegaly
30. The effect of recombinant human GH replacement therapy on lipoprotein(a) and other lipid parameters in adults with acquired GH deficiency: Results of a double-blind and placebo-controlled trial
31. Increased serum lipoprotein(a) concentrations after growth hormone (GH) treatment in patients with isolated GH deficiency
32. Hormonal regulation of serum lipoprotein(a) levels. Contrasting effects of growth hormone and insulin-like growth factor-I
33. Mortality and cancer incidence in acromegaly: A retrospective cohort study
34. Recombinant human insulin-like growth factor-I decreases serum lipoprotein(a) concentrations in normal adult men
35. Serum lipoproteins in acromegaly before and 6-15 months after transsphenoidal adenomectomy
36. A pilot scheme for improving the accuracy of serum cholesterol measurement in Scotland and Northern Ireland
37. Growth hormone specifically stimulates the expression of low density lipoprotein receptors in human hepatoma cells
38. Cholesterol and lipoprotein metabolism in aging: Reversal of hypercholesterolaemia by growth hormone treatment in old rats
39. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease
40. Variation in lipoprotein(a) concentrations among individuals with the same apolipoprotein(a) isoform is determined by the rate of lipoprotein(a) production
41. Determinants of clinical outcome and survival in acromegaly
42. Lp(a) lipoprotein as a risk factor for myocardial infarction
43. Importance of growth hormone for the induction of hepatic low density lipoprotein receptors
44. Effect of post-menopausal estrogen replacement on plasma Lp(a) lipoprotein concentrations
45. Apo(a) isoforms predict risk for coronary heart disease. A study in six populations
46. Lipoprotein(a) and atherosclerosis
47. Effect of freezing and thawing of serum on the immunoassay of lipoprotein(a)
48. Effects of acromegaly treatment and growth hormone on adipose tissue lipoprotein lipase
49. Plasma cholesterol concentration and mortality. The Whitehall study
50. The lowering of lipoprotein[a] induced by estrogen plus progesterone replacement therapy in post-menopausal women
51. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction
52. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly
53. The incidence and pathogenesis of hyperlipidaemia in 16 consecutive acromegalic patients
54. LDL subfractions in acromegaly: Relation to growth hormone and insulin-like growth factor-I
55. Blood lipids in middle-aged British men
56. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant
57. An open-label study of a growth hormone receptor antagonist (pegvisomant) in the treatment of acromegaly
58. Lipid metabolism in acromegalic patients before and after selective pituitary adenomectomy
59. The mysteries of lipoprotein(a)
60. The favourable effects of growth hormone (GH) substitution on hypercholesterolaemia in GH-deficient adults are not associated with concomitant reductions in adiposity. A 12 month placebo-controlled study
61. Growth hormone (GH) status is an independent determinant of serum levels of cholesterol and triglycerides in healthy adults
62. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group
63. Anomalies of lipoprotein pattern and fibrinolysis in acromegalic patients: Relation to growth hormone levels and insulin-like growth factor I
64. Mortality in acromegaly
65. Associations of serum high density lipoprotein and total cholesterol with total, cardiovascular, and cancer mortality in a 7-year prospective study of 10 000 men
66. Evidence for an independent relationship between plasma insulin and concentration of high density lipoprotein cholesterol and triglyceride